NanoString Announces the University of Oxford Selected as the Winning Recipient in GeoMx Digital Spatial Profiler Grant Program
“We are honored to announce that Dr.
According to Dr. Issa, “Spatial genomics has the potential to make a major impact in transplantation research. Digital Spatial Profiling will allow us to collect comprehensive biological information from our precious tissue samples, including highly informative topographic data,” stated Fadi Issa, MA, BMBCh, MSc, PhD, FRCS, Principal Investigator at the
The GeoMx Digital Spatial Profiler is currently in development and is expected to be commercially available in mid-2019. Today, Digital Spatial Profiling technology can be accessed through NanoString’s Technology Access Program (TAP). To date, over 40 customers have completed more than 55 TAP projects and processed over 1000 samples. The results from these studies highlight the performance of DSP in at least ten abstracts presented at major scientific meetings and several publications in press.
Interested parties can learn more about DSP by visiting Opens in new windowhttps://www.nanostring.com/scientific-content/technology-overview/digital-spatial-profiling-technology.
About
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit Opens in new windowwww.nanostring.com.
The
Contact:
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Source: NanoString Technologies, Inc.